Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $1.73 billion. The enterprise value is $765.92 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
JANX has 60.15 million shares outstanding. The number of shares has increased by 18.41% in one year.
| Current Share Class | 60.15M |
| Shares Outstanding | 60.15M |
| Shares Change (YoY) | +18.41% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 6.55% |
| Owned by Institutions (%) | 93.22% |
| Float | 45.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 174.65 |
| Forward PS | 2,253.66 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 76.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.86, with a Debt / Equity ratio of 0.02.
| Current Ratio | 35.86 |
| Quick Ratio | 35.76 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -12.48% and return on invested capital (ROIC) is -10.74%.
| Return on Equity (ROE) | -12.48% |
| Return on Assets (ROA) | -10.49% |
| Return on Invested Capital (ROIC) | -10.74% |
| Return on Capital Employed (ROCE) | -14.47% |
| Revenue Per Employee | $123,457 |
| Profits Per Employee | -$1.26M |
| Employee Count | 81 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.18% in the last 52 weeks. The beta is 2.82, so JANX's price volatility has been higher than the market average.
| Beta (5Y) | 2.82 |
| 52-Week Price Change | -41.18% |
| 50-Day Moving Average | 26.05 |
| 200-Day Moving Average | 26.95 |
| Relative Strength Index (RSI) | 55.44 |
| Average Volume (20 Days) | 1,147,105 |
Short Selling Information
The latest short interest is 6.95 million, so 11.55% of the outstanding shares have been sold short.
| Short Interest | 6.95M |
| Short Previous Month | 8.56M |
| Short % of Shares Out | 11.55% |
| Short % of Float | 15.43% |
| Short Ratio (days to cover) | 6.15 |
Income Statement
In the last 12 months, JANX had revenue of $10.00 million and -$101.90 million in losses. Loss per share was -$1.68.
| Revenue | 10.00M |
| Gross Profit | -66.26M |
| Operating Income | -144.29M |
| Pretax Income | -101.90M |
| Net Income | -101.90M |
| EBITDA | -142.22M |
| EBIT | -144.29M |
| Loss Per Share | -$1.68 |
Full Income StatementBalance Sheet
The company has $988.99 million in cash and $22.66 million in debt, giving a net cash position of $966.33 million or $16.07 per share.
| Cash & Cash Equivalents | 988.99M |
| Total Debt | 22.66M |
| Net Cash | 966.33M |
| Net Cash Per Share | $16.07 |
| Equity (Book Value) | 976.56M |
| Book Value Per Share | 16.24 |
| Working Capital | 970.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.42 million and capital expenditures -$979,000, giving a free cash flow of -$71.40 million.
| Operating Cash Flow | -70.42M |
| Capital Expenditures | -979,000 |
| Free Cash Flow | -71.40M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,442.88% |
| Pretax Margin | -1,018.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.41% |
| Shareholder Yield | -18.41% |
| Earnings Yield | -5.88% |
| FCF Yield | -4.12% |
Analyst Forecast
The average price target for JANX is $77.40, which is 168.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $77.40 |
| Price Target Difference | 168.75% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 79.90% |
| EPS Growth Forecast (5Y) | 17.27% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 25.33 and a Piotroski F-Score of 1.
| Altman Z-Score | 25.33 |
| Piotroski F-Score | 1 |
